ltra dose vitamin D supplementation in ventilator associated pneumonitis (VAP) patients
- Conditions
- Ventilator associated pneumonitis (VAP).
- Registration Number
- IRCT20200324046844N1
- Lead Sponsor
- Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 42
Pneumonia Severity Index (PSI) score above 51
The level of vitamin D below 20 ng/ml at the admission to the hospital
Absence of hypercalcemia at the admission to the hospital (calcium concentration above 10.8 mg/dl)
Stable hemodynamic status
Not consuming hydrochlorothiazide, digoxin and magnesium containing antacids
Absence of history of consuming vitamin D during the past four months with the dose above 1000 units
Able to be be fed enterally at the 24 to 48 hours from the admission time
Signing the consent form by the family of patients
Absence of any of these disease: hyperparathyroidism, nephrolithiasis, sarcoidosis, chronic kidney disease, cirrhosis, metabolic diseases, acquired immune deficiency syndrome (AIDS), cardiovascular disease, diabetes mellitus, cancers and autoimmune diseases
Not being pregnant
Not involved in other research projects
Presence of other types of pneumonitis
Dying earlier than 7 days of intervention
Presence of any condition leading to enteral feeding disruption during the first 5 days of intervention
If the supplementation is thought to be hazardous or being forbidden by the general practitioner
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method